Alexion Pharmaceuticals Inc.
Boston, MA
- UEI
- DKCXLGANZAN3
- CAGE
- 4EXK1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Astrazeneca Pharmaceuticals LP, ranks #93 in NAICS 325412
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- FKJ6ZGM5A7P7
- FH2MKRASLYM3
-
- SAM.gov registration date
- Physical address
- 121 Seaport Blvd, Boston, MA 02210, USA
- Website
- alexion.com
- Founded
- 1992
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $733,649 |
| FY2025 | $522,190 |
| FY2024 | $1,441,918 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $733,649 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Strensiq 80 MG | Veterans Integrated Service Network 5 (VHA) | $104,650 | |
| Strensiq 80 MG/0.8 ML INJ. | Veterans Integrated Service Network 20 (VHA) | $1,255,805 | |
| Strensiq | Veterans Integrated Service Network 20 (VHA) | $626,866 | |
| Order for pharmaceutical strensiq 80MG | Veterans Integrated Service Network 20 (VHA) | $522,487 | |
| Strensiq | Veterans Integrated Service Network 20 (VHA) | $187,948 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Ardelyx, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Recordati Rare Diseases Inc. | Bridgewater, NJ | 325411 Medicinal and Botanical Manufacturing |
| Kiniksa Pharmaceuticals (Uk), LTD. | England | 325412 Pharmaceutical Preparation Manufacturing |
| Travere Therapeutics, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Alexion Pharmaceuticals Inc., a foreign-owned Boston-based biopharmaceutical manufacturer, supplies specialized rare-disease therapeutics exclusively to the Department of Veterans Affairs as a prime contractor on full-and-open GSA Schedule contracts, with no set-aside designations across its federal footprint. The company competes entirely through the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and holds two active BPAs with the VA National Acquisition Center valued at $2.97 million (through August 7, 2027) and $4.24 million (through August 31, 2026, now expired). Alexion operates as a for-profit corporate entity with two named subsidiaries: Portola Pharmaceuticals, Inc. and Alexion Pharma International SARL.
Alexion's federal capability portfolio centers on Strensiq (inosine triphosphate), an injectable medication for perinatal/infantile- and juvenile-onset hypophosphatasia, a rare genetic metabolic disorder. Representative work includes a $1.26 million delivery order awarded by Veterans Integrated Service Network 20 on December 22, 2025 for Strensiq 80 mg/0.8 mL supply through December 21, 2026; a $626,866 delivery order from VISN 20 on December 22, 2024 for the same therapeutic; and a $104,650 BPA call issued by VISN 5 on July 21, 2026 under the older $4.24 million BPA. All work is performed from Alexion's Boston facility, with distribution to VA medical centers and clinics nationwide.
The VA dominates Alexion's customer footprint entirely. The top five VISN customer entities account for 53% of the 502 total awards in the source, but the dollar concentration is extreme: Veterans Integrated Service Network 12 alone anchors $1.13 billion of the $1.15 billion combined potential value across all awards, representing 99% of the portfolio's dollars. VISN 10, VISN 8, VISN 16, and VISN 22 collectively represent the remaining 1% and place incremental supply orders ranging from approximately $70,658 to $2.6 million per VISN. The VA National Acquisition Center holds two structural BPAs that govern the order flow across the entire VHA network.
Alexion's primary ordering vehicles are the Pharmaceuticals and Drugs GSA Schedule (195 task orders, $17.7 million combined potential value) and Federal Supply Schedule V797P5942X (246 task orders, $5.7 million combined potential value). Recent award activity shows modest volume — one award in 2024, one in 2025, and three through August 2026 — reflecting the episodic procurement pattern inherent to specialty pharmaceutical supply under standing BPA vehicles. Only one award ($1.3 million) faces ultimate completion within the next twenty-four months, presenting minimal recompete exposure in the near term. Alexion has no subcontract presence in the federal ecosystem; all 502 awards are prime awards. The combined dollars obligated across all awards total $16.9 million against $1.15 billion in potential value, indicating that the bulk of the ceiling capacity remains unobligated and reflects forward-pricing provisions built into the VA's standing therapeutic supply agreements.
Quick answers
Is Alexion Pharmaceuticals Inc. registered in SAM.gov?
Yes. Alexion Pharmaceuticals Inc.'s SAM.gov registration is active through April 27, 2027.
Which contract vehicles does Alexion Pharmaceuticals Inc. hold?
Alexion Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Alexion Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $522,190 to Alexion Pharmaceuticals Inc. in fiscal year 2025 and $2,697,757 in fiscal years 2023 through 2027.
How does Alexion Pharmaceuticals Inc. rank among federal contractors?
Alexion Pharmaceuticals Inc.'s parent company, Astrazeneca Pharmaceuticals LP, ranked #93 in NAICS 325412 in FY2025.
What is Alexion Pharmaceuticals Inc.'s most recent federal award?
Alexion Pharmaceuticals Inc.'s most recent federal contract award is Strensiq 80 MG (36C24526N0739), from Veterans Integrated Service Network 5 (VHA), on July 21, 2026.
On GovTribe
See Alexion Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors